Table 3. Study endpoints during the outcome year.
| ICS cohort | non-ICS cohort | |
|---|---|---|
| Change in HbA1c from baseline to outcome, median (IQR) | 0.18 (-0.23, 0.60) | 0.03 (-0.33, 0.50) |
| ≥ 0.5 (DCCT %) increase in HbA1c from baseline to outcome, n (%) | 179 (29.9) | 153 (25.5) |
| Addition of antidiabetic drug from baseline to outcome, n (%) | 101 (16.9) | 100 (16.7) |
| ≥ 0.5 (DCCT %) increase in HbA1c and/or addition of antidiabetic drug from baseline to outcome, n (%) | 240 (40.1) | 223 (37.2) |
| HbA1c off QOF target (>7.5%), n (%) | 209 (30.6) | 194 (28.4) |
| Change in annual rate of diabetes-related GP visits, median (IQR) | 0 (-1.01, 1.33) | -0.01 (-1.34, 1) |
| Increase in diabetes-related hospitalisation rate, n (%) | 41 (6.0) | 31 (4.5) |
| Increase in prescription rate for glucose strips, n (%) | 114 (16.7) | 75 (11.0) |
| Progression to insulin, n (%) | 28 (4.7) | 12 (2.0) |
DCCT = Diabetes Control and Complications Trial units; GP = general practice; HbA1c = glycated haemoglobin; ICS = inhaled corticosteroids; IQR = interquartile range; OCS = oral corticosteroids; QOF = Quality and Outcomes Framework.